Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARF6 | P62330 | 3/20 | 0.39 |
| ▸ | PLAT | P00750 | 2/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313546 | 0.93 | ARF6 (0.41) | ARF6PLATTNKS2TRPV1CA12 | |
| SCHEMBL10275534 | 0.89 | TNKS2 (0.40) | ARF6PLATTNKS2PGRNR3C2 | |
| SCHEMBL10276415 | 0.88 | ARF6 (0.38) | ARF6TNKS2TRPV1CA12CA9 | |
| SCHEMBL10276150 | 0.87 | KDM4E (0.42) | ARF6PLATTNKS2TRPV1MAPT | |
| SCHEMBL10275606 | 0.87 | CA12 (0.43) | PLATTRPV1CA12CA9MAPT | |
| SCHEMBL10275272 | 0.87 | MEN1 (0.43) | TNKS2MAPT | |
| SCHEMBL10275539 | 0.86 | FLT3 (0.39) | ARF6TNKS2PDE3BPDE3A | |
| SCHEMBL10313518 | 0.84 | CA12 (0.41) | PLATTRPV1CA12CA9MAPT | |
| SCHEMBL10275273 | 0.83 | PLAT (0.40) | ARF6PLATMAPTPDE2APGR | |
| SCHEMBL10276351 | 0.81 | TRPV1 (0.37) | ARF6TNKS2TRPV1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011035518-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | 辽宁利锋科技开发有限公司 (CN) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | ARF6 3355/4885PLAT 2180/4885TNKS2 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.